[1]
|
韩家鑫, 徐亮, 等. 肝细胞癌早期筛查和诊断的研究进展[J]. 临床肝胆病杂志, 2023, 39(6): 1468-1475.
|
[2]
|
Zhou, M., Wang, H., Zeng, X., et al. (2019) Mortality, Morbidity, and Risk Factors in China and Its Provinces, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet, 394, 1145-1158. https://doi.org/10.1016/S0140-6736(19)30427-1
|
[3]
|
Chen, W., Zheng, R., Baade, PD., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[4]
|
Pinto, Marques, H., Gomes, Da Silva, S., De Martin, E., et al. (2020) Emerging Biomarkers in HCC Patients: Current Status. International Journal of Surgery, 82, 70-76. https://doi.org/10.1016/j.ijsu.2020.04.043
|
[5]
|
Wang, W. and Wei, C. (2020) Advances in the Early Diagnosis of Hepatocellular Carcinoma. Genes & Diseases, 7, 308-319. https://doi.org/10.1016/j.gendis.2020.01.014
|
[6]
|
Tzartzeva, K., Obi, J., Rich, N.E., et al. (2020) Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis: A Meta-Analysis. Gastroenterology, 154, 1706-1718.E1. https://doi.org/10.1053/j.gastro.2018.01.064
|
[7]
|
Roberts, L.R., Sirlin, C.B., Zaiem, F., et al. (2021) Imaging for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Hepatology, 67, 401-421. https://doi.org/10.1002/hep.29487
|
[8]
|
Nadarevic, T., Collia, A., Giljaca, V., et al. (2022) Magnetic Resonance Imaging for the Diagnosis of Hepatocellular Carcinoma in Adults with Chronic Liver Disease. Cochrane Database of Systematic Reviews, 5, CD014798. https://doi.org/10.1002/14651858.CD014798.pub2
|
[9]
|
Inoue, T., Kudo, M., Komuta, M., et al. (2022) Assessment of Gd-EOB-DTP-enhanced MRI for HCC and Dysplastic Nodules and Comparison of Detection Sensitivity versus MDCT. Journal of Gastroenterology, 47, 1036-1047. https://doi.org/10.1007/s00535-012-0571-6
|
[10]
|
Gao, F., Wei, Y., Zhang, T., et al. (2022) New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients. Frontiers in Oncology, 12, Article 812832. https://doi.org/10.3389/fonc.2022.812832
|
[11]
|
Wilson, S.R., Kim, T.K., Jang, H.J., et al. (2021) Enhancement Patterns of Focal Liver Masses: Discordance Between Contrast-Enhanced Sonography and Contrast-Enhanced CT and MRI. American Journal of Roentgenology, 189, W7-W12. https://doi.org/10.2214/AJR.06.1060
|
[12]
|
Fraquelli, M., Nadarevic, T., Colli, A., et al. (2022) Contrast-Enhanced Ultrasound for the Diagnosis of Hepatocellular Carcinoma in Adults with Chronic Liver Disease. Cochrane Database of Systematic Reviews, 9, CD013483. https://doi.org/10.1002/14651858.CD013483.pub2
|
[13]
|
Aubé, C., Oberti, F., Lonjon, J., et al. (2021) EASL and AASLD Recommendations for the Diagnosis of HCC to the Test of Daily Practice. Liver International, 37, 1515-1525. https://doi.org/10.1111/liv.13429
|
[14]
|
谢光军, 郭云虎, 漆兴美, 等. 腹腔镜超声引导下射频消融术治疗小肝癌的相关性研究[J]. 腹腔镜外科杂志, 2014, 19(1): 25-27.
|
[15]
|
Ganesan, P. and Kulik, L.M. (2023) Hepatocellular Carcinoma: New Developments. Clinical Liver Disease, 27, 85-102. https://doi.org/10.1016/j.cld.2022.08.004
|
[16]
|
江哲龙, 魏志鸿, 张坤, 等. 交替阻断半肝入肝血流在解剖性肝中叶切除术中的应用[J]. 局解手术学杂志, 2019, 28(1): 60-63.
|
[17]
|
胡文豪, 王洪东, 沈超楹, 等. 解剖性与非解剖性肝切除治疗原发性肝细胞癌临床疗效比[J]. 中国现代手术学杂志, 2019, 23(3): 172-178.
|
[18]
|
黄俊海, 黄磊, 陈彬, 等. 腹腔镜与开腹肝切除术治疗原发性肝细胞癌的疗效对比研究及术后2年复发的影响因素分析[J]. 现代生物医学进展, 2022, 22(19): 3684-3688.
|
[19]
|
李照阳. 腹腔镜与开腹肝切除术治疗原发性大肝癌患者疗效比较[J]. 中国民康医学, 2020, 5(32): 11-13.
|
[20]
|
郭毅, 王磊, 刘康伟, 等. 机器人辅助与腹腔镜肝切除治疗肝脏肿瘤疗效与安全性的Meta分析[J]. 中国普通外科杂志, 2022, 31(1): 8-21.
|
[21]
|
Ince, V., Sahin, T., Akbulut, S., et al. (2022) Liver Transplantation for Hepatocellular Carcinoma: Historical Evolution of Transplantation Criteria. World Journal of Clinical Cases, 10, 10413-10427. https://doi.org/10.12998/wjcc.v10.i29.10413
|
[22]
|
Li, J., Yan, LN., Yang, J., et al. (2019) Indicators of Prognosis after Liver Transplantation in Chinese Hepatocellular Carcinoma Patients. World Journal of Gastroenterology, 15, 4170-4176. https://doi.org/10.3748/wjg.15.4170
|
[23]
|
Kulik, L., Heimbach, J.K., Zaiem, F., et al. (2018) Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis. Hepatology, 67, 381-400. https://doi.org/10.1002/hep.29485
|
[24]
|
Hasegawa, K., Aoki, T., Ishizawa, T., et al. (2021) Comparison of the Therapeutic Outcomes Between Surgical Resection and Percutaneous Ablation for Small Hepatocellular Carcinoma. Annals of Surgical Oncology, 21, S348-S355. https://doi.org/10.1245/s10434-014-3585-x
|
[25]
|
Feng, Q., Chi, Y., Liu, Y., et al. (2020) Efficacy and Safety of Percutaneous Radiofrequency Ablation versus Surgical Resection for Small Hepatocellular Carcinoma: A Meta-Analysis of 23 Studies. Journal of Cancer Research and Clinical Oncology, 141, 1-9. https://doi.org/10.1007/s00432-014-1708-1
|
[26]
|
黎欣怡. 危险部位肝癌的射频消融治疗进展[J]. 临床放射学杂志, 2023, 42(10): 1699-1702.
|
[27]
|
Tumen, D., Heumann, P., Gulowk., et al. (2022) Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines, 10, Article 3202. https://doi.org/10.3390/biomedicines10123202
|
[28]
|
Kalogeridi, M.A., Zygogianni, A., Kyrgias, G., et al. (2021) Role of Radiotherapy in the Management of Hepatocellular Carcinoma: A Systematic Review. World Journal of Hepatology, 7, 101-112. https://doi.org/10.4254/wjh.v7.i1.101
|
[29]
|
Yin, X.L. and Xu, Q. (2022) Progress in Research on Radiotherapy of Hepatocellular Carcinoma. Modern Oncology, 24, 2989-2992.
|
[30]
|
Jiang, X., Yang, J.J. and Li, H. (2016) Clinical Effect of Brachy Therapy with 125I Seed Implantation in Treatment of Malignant Hepatopancreatobiliary Tumors. Journal of Clinical Hepatology, 32, 2300-2304.
|
[31]
|
Li, M.X. and Lv, Yi. (2023) Therapeutic Value of Yttrium-90 Microsphere in the Treatment of Primary Liver Cancer. Modern Oncology, 21, 2859-2863.
|
[32]
|
Llovet, J.M., Ricci, S., Mazzaferro, V., et al. (2022) Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390.
|
[33]
|
Kudo, M. (2018) Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma. Liver Cancer, 7, 215-224. https://doi.org/10.1159/000492533
|
[34]
|
Kudo, M., Finn, R.S., Qin, S., et al. (2018) Lenvatinib versus Sorafenib in First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. The Lancet, 391, 1163-1173. https://doi.org/10.1016/S0140-6736(18)30207-1
|
[35]
|
Bruix, J., Qin, S., Merle, P., et al. (2017) Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebocontrolled, Phase 3 Trial. The Lancet, 389, 56-66. https://doi.org/10.1016/S0140-6736(16)32453-9
|
[36]
|
Zhu, A.X., Park, J.O., Ryoo, B.Y., et al. (2022) Ramucirumab versus Placebo as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial. The Lancet Oncology, 16, 859-870. https://doi.org/10.1016/S1470-2045(15)00050-9
|
[37]
|
Bi, F., Qin, S., Gu, S., et al. (2020) Donafenib versus Sorafenib as Firstline Therapy in Advanced Hepatocellular Carcinoma: An Openlabel, Randomized, Multicenter Phase Ⅱ/Ⅲ Trial. Journal of Clinical Oncology, 38, Article 4506. https://doi.org/10.1200/JCO.2020.38.15_suppl.4506
|
[38]
|
Qin, S., Chan, S.L., Sukeepaisarnjaroen, W., et al. (2019) A Phase Ⅱ Study of the Efficacy and Safety of the MET Inhi Bitor Capmatinib (INC280) in Patients with Advanced Hepat Ocellular Carcinoma. Therapeutic Advances in Medical Oncology, 11, 1-12.
|
[39]
|
Foerster, F., Gairing, S.J., Ilyas, S.I, et al. (2022) Emerging Immunotherapy for HCC: A Guide for Hepatologists. Hepatology, 75, 1604-1626. https://doi.org/10.1002/hep.32447
|
[40]
|
Song, X., Kelley, R.K., Khan, A.A, et al. (2023) Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research, 29, 754-763. https://doi.org/10.1158/1078-0432.CCR-22-1983
|
[41]
|
Zhu, A.X., Finn, R.S., Edeline, J., et al. (2018) Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. The Lancet Oncology, 19, 940-952.
|
[42]
|
Qin, S., Ren, Z., Meng, Z., et al. (2020) Camrelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma: A Multicentre, Open-Label, Parallel-Group, Randomised, Phase 2 Trial. The Lancet Oncology, 21, 571-580. https://doi.org/10.1016/S1470-2045(20)30011-5
|
[43]
|
Qin, S., Finn, R.S., Kudo, M., et al. (2019) RATIONALE 301 Study:Tislelizumab versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma. Future Oncology, 15, 1811-1822. https://doi.org/10.2217/fon-2019-0097
|
[44]
|
Kraehenbuehl, Weng, C.H., Eghbali, S., et al. (2022) Enhancing Immunotherapy in Cancer by Targeting Emerging Immunomodulatory Pathways. Nature Reviews Clinical Oncology, 19, 37-50. https://doi.org/10.1038/s41571-021-00552-7
|
[45]
|
Kudo, M., Ueshimak, Ikedam, et al. (2020) Randomised, Multicentre Prospective Trial of Transarterial Chemoembolisation (TACE) Plus Sorafenib as Compared with TACE Alone in Patients with Hepatocellular Carcinoma: TACTICS Trial. Gut, 69, 1492-1501. https://doi.org/10.1136/gutjnl-2019-318934
|
[46]
|
Lencionir, R., Llovet, J.M., Han, G., et al. (2016) Sorafenib or Placebo Plus TACE with Doxorubicin-Eluting Beads for Intermediate Stage HCC: The SPACE Trial. Journal of Hepatology, 4, 1090-1098. https://doi.org/10.1016/j.jhep.2016.01.012
|
[47]
|
He, M.K., Zou, R.H., Li, Q.J., et al. (2018) Phase Ⅱ Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. CardioVascular and Interventional Radiology, 41, 734-743. https://doi.org/10.1007/s00270-017-1874-z
|
[48]
|
Chiang, C.L., Chana, C.Y., Chiuk, W.H., et al. (2019) Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy. Frontiers in Oncology, 9, Article 1157. https://doi.org/10.3389/fonc.2019.01157
|